Emyria Ltd (ASX:EMD) Michael Winlo tells Proactive the company has been accepted into the US National Institute of Health’s (NIH) Preclinical Screening Platform for Pain program. The NIH’s National Institute of Neurological Disorders and Stroke (NINDS) — also the leading funder of neurological research in the US — will run the study as part of a broader initiative to stem the opioid public health crisis.
Hashtag: #Emyria
The issuer is solely responsible for the content of this announcement.
Sony has started its 2026 PlayStation Store Black Friday sale four weeks ahead of Black…
The Democratic Party swept the 2026 US midterm elections, securing control of both houses of…
The Union Cabinet has approved a two-year extension to the service tenure for Agniveers under…
The Kerala State Lottery Department announced the DhanaLekshmi DL-76 result for November 4, 2026. The…
India took a 1-0 series lead in their one-day international clash against New Zealand after…
Sophie Devine picked up a four-wicket haul to seal a tight, low-scoring victory for Perth…